That is something I wondered about when I was first looking at the company. Yes competition is possible (inevitable) but I see them as having first mover advantage with significant partnerships already in place. Its really a relatively new development (I think the company has been in it for ~10 years). They do have patents (not a lot) 4 I believe and 100 or so pending (total worldwide). I also liked that they are continuing to move the technology (such as going outside of Oncology and advancing it for BiSpecifics).
I was not familiar with Igencia. A recent IPO (MRSN) is doing something similar (along the lines of delivering more drug to target).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.